Virion Therapeutics - Developing checkpoint inhibitor-powered chronic viral disease vaccines with ChiVax-gD Technologies
Employees: 1-10
Total raised: $5.42M
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | Puget Soun... | pugetsound... |
| - | Robin Hood... | robinhoodv... |
| - | Mid Atlant... | bioangels.... |
| - | Keiretsu F... | keiretsufo... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.09.2018 | Series A | $5M | - |
| - | - | $417.5K | Robin Hood... |
Mentions in press and media 9
| Date | Title | Description |
| 23.07.2025 | VIRION VACCINE INDUSTRY & TRADE INC BEGINS USD 7 M INVESTMENT ROUND FOR STATE-OF-THE-ART VET VACCINE PRODUCTION | The main purpose of VIRION is producing veterinary vaccines FMD (inactivated), BT, POX, PPR, New Castle, Gumboro, Marek, and IB ISTANBUL, -, TURKEY, July 23, 2025 /EINPresswire.com/ -- VIRION aims to establish a sustainable and profitable v... |
| 07.05.2025 | Virion Therapeutics Reports New Data from Two Clinical Presentations at EASL 2025, including Rapid and Profound Hepatitis B Surface Antigen Declines with the First VRON-0200 Containing Combination The... | This novel and exciting approach.....may represent a paradigm shift in treatment approaches that could bring new therapies that include VRON-0200 to produce meaningful Functional Cure rates.” — Professor Ed Gane, M.D.PHILADELPHIA, PA, UNITE... |
| 05.06.2024 | Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress | Highlights from the Data Presentation Initial immunogenicity (n=9) and ongoing safety data (n=13) presented in chronically HBV-infected patients following a single, low dose, prime-only intramuscular injection of VRON-0200 VRON-0200 was wel... |
| 27.09.2018 | Virion Therapeutics Raises $5M in Series A Funding | Virion Therapeutics, LLC, a Philadelphia, PA-based startup advancing innovative, immune-based therapies for the treatment of chronic viral-associated cancers and viral infections, raised $5m in Series A funding. Backers included: – Robin Ho... |
| 26.09.2018 | Virion Therapeutics Raises $5 Million | A new Philadelphia-based start-up, Virion Therapeutics, LLC spun out of The Wistar Institute, will work to advance innovative, immune-based therapies for the treatment of chronic viral-associated cancers and viral infections utilizing the f... |
| 17.09.2018 | Virion Therapeutics Raises $4M | Wistar Institute spinout company Virion Therapeutics raised a $4 million angel round, according to an SEC filing. The immunotherapy company is working on a path to commercialization for a set of vaccines aimed at treating certain types of c... |
| 17.09.2018 | Virion Therapeutics raises $4M to continue work on cancer, viral infection treatments | Wistar Institute spinout company Virion Therapeutics raised a $4 million angel round, according to an SEC filing. The immunotherapy company is working on a path to commercialization for a set of vaccines aimed at treating certain types of c... |
| 17.09.2018 | Virion Therapeutics Raises $4M | Wistar Institute spinout company Virion Therapeutics raised a $4 million angel round, according to an SEC filing. The immunotherapy company is working on a path to commercialization for a set of vaccines aimed at treating certain types of c... |
| - | Robin Hood Ventures Invests $417,500 in Virion Therapeutics, LLC | Robin Hood Ventures Invests $417,500 in Virion Therapeutics, LLC’s Angel Round |